Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The prevalence of altered body image in patients with primary brain tumors: an understudied population.
Rowe L, Vera E, Acquaye A, Crandon S, Shah V, Bryla C, Wu J, Wall K, Siegel C, Reyes J, Penas-Prado M, Leggiero N, Cordova C, Burton E, Antony R, Boris L, Aboud O, Vyas Y, Mathen P, Gilbert M, Camphausen K, Mendoza T, Armstrong T. Rowe L, et al. J Neurooncol. 2020 Apr;147(2):397-404. doi: 10.1007/s11060-020-03433-8. Epub 2020 Feb 24. J Neurooncol. 2020. PMID: 32096067 Free PMC article.
NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop Proceedings.
Theeler BJ, Dalal Y, Monje M, Shilatifard A, Suvà ML, Aboud O, Camphausen K, Cordova C, Finch E, Heiss JD, Packer RJ, Romo CG, Aldape K, Penas-Prado M, Armstrong T, Gilbert MR. Theeler BJ, et al. Neurooncol Adv. 2020 Jan 16;2(1):vdaa007. doi: 10.1093/noajnl/vdaa007. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 32642676 Free PMC article. Review.
Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors-A prospective study and guidelines for clinical testing.
Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, Wen M, Patel S, Movahed-Ezazi M, Faustin A, Spino-Keeton M, Roberts LG, Maloku E, Drexler SA, Liechty BL, Pisapia D, Krasnozhen-Ratush O, Rosenblum M, Shroff S, Boué DR, Davidson C, Mao Q, Suchi M, North P, Hopp A, Segura A, Jarzembowski JA, Parsons L, Johnson MD, Mobley B, Samore W, McGuone D, Gopal PP, Canoll PD, Horbinski C, Fullmer JM, Farooqui MS, Gokden M, Wadhwani NR, Richardson TE, Umphlett M, Tsankova NM, DeWitt JC, Sen C, Placantonakis DG, Pacione D, Wisoff JH, Teresa Hidalgo E, Harter D, William CM, Cordova C, Kurz SC, Barbaro M, Orringer DA, Karajannis MA, Sulman EP, Gardner SL, Zagzag D, Tsirigos A, Allen JC, Golfinos JG, Snuderl M. Galbraith K, et al. Neurooncol Adv. 2023 Jun 26;5(1):vdad076. doi: 10.1093/noajnl/vdad076. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37476329 Free PMC article.
Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop.
Penas-Prado M, Wu J, Cahill DP, Brat DJ, Costello JF, Kluetz PG, Cairncross JG, van den Bent M, Verhaak RGW, Aboud O, Burger P, Chang SM, Cordova C, Huang RY, Rowe LS, Taphoorn MJB, Gilbert MR, Armstrong TS; NCI-CONNECT Oligodendroglioma Workshop. Penas-Prado M, et al. Neurooncol Adv. 2019 Dec 6;2(1):vdz048. doi: 10.1093/noajnl/vdz048. eCollection 2020 Jan-Dec. Neurooncol Adv. 2019. PMID: 33289010 Free PMC article. Review.
34 results